Get up to date with the latest HitGen articles and join us in the events
In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information